Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (221-230 of 487) with videos related to

Pageof 49
Sort By:
JAMA Network Open|October 7, 2021
Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world DataSamantha Wilkinson, Alind Gupta, Nicolas Scheuer, et al.
Oncoscience|August 16, 2014
Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint HypothesisDaniela Egas-Bejar, Pete M Anderson, Rishi Agarwal, et al.
Oncoscience|January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision makingSmruti J Vidwans, Michelle L Turski, Filip Janku, et al.
Plos One|August 15, 2014
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumorsYunyun Jiang, Vivek Subbiah, Filip Janku, et al.
Trends in Cancer|September 13, 2023
Variant allele frequency: a decision-making tool in precision oncology?Luca Boscolo Bielo, Dario Trapani, Matteo Repetto, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
Current Oncology Reports|November 8, 2024
Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art ReviewVivek Podder, Shreyas Bellur, Kim Margolin, et al.
Journal of Surgical Oncology|February 27, 2010
Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approachDavid Reynoso, Vivek Subbiah, Jonathan C Trent, et al.
Clinical Lung Cancer|August 14, 2023
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case SeriesJeremy Fricke, Joshua Wang, Natalie Gallego, et al.
Cancers|September 5, 2019
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy TargetsJason Roszik, Abir Khan, Anthony P Conley, et al.
Pageof 49

Showing results (221-230 of 487) with videos related to

Sort By:
Pageof 49
JAMA Network Open|October 7, 2021
Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world DataSamantha Wilkinson, Alind Gupta, Nicolas Scheuer, et al.
Oncoscience|August 16, 2014
Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint HypothesisDaniela Egas-Bejar, Pete M Anderson, Rishi Agarwal, et al.
Oncoscience|January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision makingSmruti J Vidwans, Michelle L Turski, Filip Janku, et al.
Plos One|August 15, 2014
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumorsYunyun Jiang, Vivek Subbiah, Filip Janku, et al.
Trends in Cancer|September 13, 2023
Variant allele frequency: a decision-making tool in precision oncology?Luca Boscolo Bielo, Dario Trapani, Matteo Repetto, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
Current Oncology Reports|November 8, 2024
Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art ReviewVivek Podder, Shreyas Bellur, Kim Margolin, et al.
Journal of Surgical Oncology|February 27, 2010
Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approachDavid Reynoso, Vivek Subbiah, Jonathan C Trent, et al.
Clinical Lung Cancer|August 14, 2023
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case SeriesJeremy Fricke, Joshua Wang, Natalie Gallego, et al.
Cancers|September 5, 2019
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy TargetsJason Roszik, Abir Khan, Anthony P Conley, et al.
Pageof 49